Expandable esophageal stents: Initial experience with a new nitinol stent

Self-Expanding Nitinol Stent for Malignant Obstructive Dysphagia–Initial Experience

“…Procedure-related mortality was low (3%) and significant morbidity also low (one transient melena and one partial stent migration -6%). This compares well with the series of Cwikiel et al 7 in which one patient of 40 died three days after stenting, and the series of Raijman et al 8 in which two patients of 14 died one and six days respectively after the procedure, one from aspiration pneumonia and the other from myocardial infarction.…”

Palliative treatment of obstructing esophageal cancer with nitinol stents: value, safety, and long-term results.

“…[4, [26][27][28][29]. One patient had a single hematemesis withoutfurther problems [28], one stent migrated [29], and two were placed incorrectly [30].…”

“…One patient had a single hematemesis withoutfurther problems [28], one stent migrated [29], and two were placed incorrectly [30]. One patient died of aspiration pneumonia that was directly related to stent placement [30], one died from a pulmonary embolus on the day of stent insertion [28], and another had a lethal myocardial infarction 6 days after stent placement.…”

Diagnostic and Therapeutic Procedures in Gastroenterology

“…In addition to high rates of technical success, SEMS are highly efficacious in their ability to palliate dysphagia and close malignant fistulae. Multiple case series and meta-analyses performed over the past 20 years suggest immediate improvement in clinical symptoms in 90-100% of patients (Cook and Dehn 1996;Christie et al 2001;Bethge et al 1998;Raijman et al 1994Raijman et al , 1998Song et al 1994;Fiorini et al 1995;De Palma et al 1995Moores and Ilves 1996;Lam et al 1999;Toikkanen et al 2000;Cordero and Moores 2000;Vakil et al 2001;Razzaq et al 2001;McGrath et al 2001;Kostopoulos et al 2003;Johnson et al 2006;Costamagna et al 2006;Sundelof et al 2007;Xinopoulos et al 2005). Despite these high technical and initial clinical success rates, the need for re-intervention remains significant with up to 1/3 of patients experiencing recurrent dysphagia from tumor in-growth or tissue hyperplasia at the proximal or distal stent margins.…”